Adalimumab


Thông tin thuốc gốc
Chỉ định và Liều dùng
Subcutaneous
Rheumatoid arthritis
Adult: 40 mg as a single dose every other wk. May increase to wkly dosing when used as monotherapy.

Subcutaneous
Ankylosing spondylitis, Psoriatic arthritis
Adult: 40 mg as a single dose every other wk.

Subcutaneous
Plaque psoriasis
Adult: Initially, 80 mg. Maintenance: 40 mg every other wk beginning 1 wk after 1st dose.

Subcutaneous
Juvenile idiopathic arthritis
Child: ≥4 yr 15 to <30 kg: 20 mg every other wk; ≥30 kg: 40 mg every other wk.

Subcutaneous
Crohn's disease, Ulcerative colitis
Adult: Moderate to severe active disease: Initially, 160 mg (given as four 40-mg inj in 1 day or as two 40-mg inj for 2 consecutive days), then 80 mg 2 wk after the initial dose (day 15). Maintenance: After 2 wk (day 29), 40 mg every other wk, may increase to 40 mg wkly if needed. Review treatment if no response w/in 8 (ulcerative colitis) or 12 (Crohn’s disease) wk of therapy.
Thận trọng
Patient w/ pre-existing or recent onset central or peripheral nervous system demyelinating disorders, heart failure or decreased left ventricular function; at risk of hepatitis B virus (HBV) infection. Reactivation and new onset of TB infection. Patient who travelled to or resided in regions where TB is endemic. Elderly. Pregnancy and lactation.
Phản ứng phụ
Upper resp tract infection, pulmonary and extrapulmonary (e.g. disseminated) TB, nasopharyngitis, sinusitis, headache, pyrexia, musculoskeletal pain, CVA, pulmonary embolism, DVT, alopecia, inj site reactions (itching, erythema, haemorrhage, pain or swelling), hepatobiliary disorders, liver failure, sarcoidosis, Merkel cell carcinoma, new or worsening psoriasis (all sub-types e.g. pustular and palmoplantar). Rarely, pancytopenia, aplastic anaemia, central and peripheral demyelinating events, lupus and related conditions, Stevens-Johnson syndrome.
Potentially Fatal: Sepsis, opportunistic infections, TB, HBV reactivation, other malignancies (e.g. leukaemia, lymphoma, hepatosplenic T-cell lymphoma), haematological, neurological and autoimmune reactions, anaphylaxis, angioneurotic oedema.
MonitoringParameters
Perform tuberculin skin test and HBV screening prior to treatment. Monitor for signs and symptoms of infection prior to, during and following treatment.
Tương tác
Increased risk of serious infections w/ other biologic disease-modifying antirheumatic drugs (e.g. abatacept, anakinra), rituximab. May increase immunosuppressant effect w/ tocilizumab, live vaccines.
Tác dụng
Description: Adalimumab is a recombinant DNA-derived human Ig G1 monoclonal antibody. It binds to human tumour necrosis factor alfa (TNF-α), thus interfering w/ cytokine-driven inflammatory processes.
Pharmacokinetics:
Absorption: Bioavailability: 64%. Time to peak plasma concentration: Approx 3-8 days.
Distribution: It crosses the placenta; enters breast milk. Volume of distribution: 4.7-6 L.
Excretion: Mean terminal half-life: Approx 2 wk.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
References
Anon. Adalimumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/09/2014.

Buckingham R (ed). Adalimumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/09/2014.

Humira Injection, Solution (Abbvie Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 30/09/2014.

Humira Injection. U.S. FDA. https://www.fda.gov/. Accessed 30/09/2014.

Joint Formulary Committee. Adalimumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/09/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Adalimumab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 30/09/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Adalimumab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in